1. Home
  2. KVUE vs CBRS Comparison

KVUE vs CBRS Comparison

Compare KVUE & CBRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$19.79

Market Cap

34.2B

ML Signal

HOLD

Logo Cerebras Systems Inc. Class A Common Stock

CBRS

Cerebras Systems Inc. Class A Common Stock

BUY

Current Price

$108.89

Market Cap

39.0B

Sector

Technology

ML Signal

BUY

Company Overview

Basic Information
Metric
KVUE
CBRS
Founded
2022
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Semiconductors
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
34.2B
39.0B
IPO Year
2023
2024

Fundamental Metrics

Financial Performance
Metric
KVUE
CBRS
Price
$19.79
$108.89
Analyst Decision
Hold
Strong Buy
Analyst Count
14
11
Target Price
$19.50
★ $291.64
AVG Volume (30 Days)
★ 16.5M
7.3M
Earning Date
10-30-2026
11-12-2026
Dividend Yield
★ 4.41%
N/A
EPS Growth
★ 40.74
N/A
EPS
★ 0.48
N/A
Revenue
★ $15,124,000,000.00
N/A
Revenue This Year
$3.12
$73.94
Revenue Next Year
$2.38
$232.73
P/E Ratio
$39.79
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$14.02
$115.13
52 Week High
$20.13
$265.63

Technical Indicators

Market Signals
Indicator
KVUE
CBRS
Relative Strength Index (RSI) 73.12 23.78
Support Level $18.67 N/A
Resistance Level $20.09 $221.60
Average True Range (ATR) 0.31 9.19
MACD 0.25 -5.21
Stochastic Oscillator 98.52 1.74

Price Performance

Historical Comparison
KVUE
CBRS

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

About CBRS Cerebras Systems Inc. Class A Common Stock

Cerebras Systems Inc is an AI company. It designs the world's fastest AI infrastructure for training and inference. The company builds the world's largest semiconductor as well as the AI systems to power, cool, and feed the processors data. It develops software to link these systems together into industry-leading supercomputers that are simple to use even for the most complicated AI work, using familiar ML frameworks like PyTorch. Customers use its supercomputers to train industry-leading models. The company uses these supercomputers to run inference at speeds unobtainable from alternative commercial technologies. It delivers these AI capabilities to its customers on-premise and via the cloud. The company generates the majority of its revenue from the USA.

Share on Social Networks: